Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis
- 184 Downloads
Many studies have investigated the association between Cyclin D1 (CCND1) G870A polymorphism and lung cancer risk, but the impact of CCND G870A polymorphism on lung cancer is unclear owing to the obvious inconsistence among those studies. This study aimed to quantify the strength of association between CCND1 G870A polymorphism and lung cancer risk. We searched the PubMed, Embase, and Wangfang databases for articles on studies relating the CCND1 G870A polymorphism to the risk of lung cancer in humans. We estimated summary odds ratios (ORs) with their confidence intervals (CIs) to assess the association. Meta-analyses of total studies showed that CCND1 G870A polymorphism was associated with lung cancer risk under three genetic models (ORA versus G = 1.13, 95 % CI 1.03–1.24; ORAA versus GG = 1.20, 95 % CI 1.07–1.35; ORAA versus AG + GG = 1.23, 95 % CI 1.02–1.50). Meta-analyses of studies with high quality showed that CCND1 G870A polymorphism was associated with lung cancer risk under two genetic models (ORA versus G = 1.08, 95 % CI 1.02–1.15; ORAA versus GG = 1.17, 95 % CI 1.04–1.32). Subgroup analyses by ethnicity and sensitivity analyses further identified the significant association above. No evidence of publication bias was observed. Meta-analyses of available data show a significant association between the CCND1 G870A polymorphism and lung cancer risk, and CCND1 G870A polymorphic variant A contributes to increased risk of lung cancer.
KeywordsCyclin D1 Lung cancer Gene polymorphism Meta-analysis
We thank Fei Zhang, Xiangya Hospital of Changsha, for her statistical support.
No external funding was either sought or obtained for this study.
Conflicts of interest
- 14.Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Cyclin d1 (ccnd1) a870g gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (nsclc) patients. Lung Cancer. 2006;51:303–11.CrossRefPubMedGoogle Scholar
- 17.Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Landi S, Gemignani F, Hall J, Brennan P. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case–control study in Central Europe. Cancer Res. 2006;66:8280–6.CrossRefPubMedGoogle Scholar
- 21.Petitti DB. Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine (2nd ed). New York: Oxford University Press; 2000.Google Scholar
- 30.A Tobias Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–17.Google Scholar
- 35.Wang R, Zhang JH, Li Y, Wen D, Wei L. The association of cyclin d1(a870g)polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364–6. Article in Chinese.Google Scholar
- 36.Li QP, Deng YJ, Xiao CJ, Yang HS. Comparative study of polymorphism of cyclin dl gene in patients with non small cell lung cancer from Xuanwei and Kunming. Shandong Yi Yao. 2009;49:1–3. Article in Chinese.Google Scholar
- 38.Wang Q, Jiang YX, Li GF, Liu X, Wang WW, Deng J, Chen N. The relationship between the cyclin d1(ccndi)a870g gene polymorphism and non small cell lung cancer in Yunnan. Med Philos. 2008;29:36–8. Article in Chinese.Google Scholar